| 17.84 -0.5 (-2.73%) | 03-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 22.76 | 1-year : | 26.58 |
| Resists | First : | 19.48 | Second : | 22.76 |
| Pivot price | 18.09 |
|||
| Supports | First : | 16.38 | Second : | 14.47 |
| MAs | MA(5) : | 18.13 |
MA(20) : | 17.72  |
| MA(100) : | 14.26 |
MA(250) : | 31.6 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 52 |
D(3) : | 60.4 |
| RSI | RSI(14): 55.8 |
|||
| 52-week | High : | 62.75 | Low : | 5.94 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ MLTX ] has closed above bottom band by 32.0%. Bollinger Bands are 68.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 19.35 - 19.45 | 19.45 - 19.53 |
| Low: | 17.52 - 17.62 | 17.62 - 17.7 |
| Close: | 17.69 - 17.85 | 17.85 - 17.97 |
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
Wed, 11 Mar 2026
MoonLake price target raised to $70 from $45 at Clear Street - TipRanks
Wed, 11 Mar 2026
Clear Street raises Moonlake stock price target on IL-17 data - Investing.com
Tue, 10 Mar 2026
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Widening Annual Net Loss Amid Share Price Gains - simplywall.st
Sat, 07 Mar 2026
TD Asset Management Inc Lowers Holdings in MoonLake Immunotherapeutics $MLTX - MarketBeat
Tue, 03 Mar 2026
MoonLake Immunotherapeutics (MLTX) Is Down 6.3% After Wider 2025 Loss And SLK BLA Timeline Update – Has The Bull Case Changed? - Sahm
Mon, 02 Mar 2026
Goldman Questions MoonLake Immunotherapeutics’ (MLTX) Sonelokimab Approval Odds Despite Pipeline Update - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 10.7 (%) |
| Held by Institutions | 81.3 (%) |
| Shares Short | 7,270 (K) |
| Shares Short P.Month | 7,180 (K) |
| EPS | -3.53 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.26 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34 % |
| Return on Equity (ttm) | -60.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -196 (M) |
| Levered Free Cash Flow | -120 (M) |
| PE Ratio | -5.06 |
| PEG Ratio | 0 |
| Price to Book value | 4.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|